Palvella Therapeutics Advances Phase 3 Study on QTORIN Gel for Rare Disease
I'm PortAI, I can summarize articles.
Palvella Therapeutics, Inc. is advancing a Phase 3 clinical study titled ‘SELVA’ to evaluate the safety and efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel for treating microcystic lymphatic malformations. The study involves approximately 40 participants and aims to assess treatment effects over 24 weeks. It began on January 16, 2024, with primary completion expected in 2025. Positive results could influence Palvella's stock performance and attract investor interest, especially with FDA involvement. Competitors in the rare disease sector are also monitoring the study's progress.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments